Drug

PF-06412562 clinical trials

Also written PF-06412562.

studies test it: 10
open now: 0
in phase 3: 0
first study started: 2013

How studies write it

Studies that test it under each name

Name

PF-06412562 3mg BID: 2
PF-06412562 3mg: 2

Development codes

PF-06412562: 5

Studies by the year they started

10 studies that test it; most in 2014 (3)

Studies that test PF-06412562, by start year
Year	Studies
2013	1
2014	3
2015	2
2017	1
2018	2
2021	1

By phase

A phase 1/2 study counts in both.

Early Phase 1: 1
Phase 1: 8
Phase 2: 1

What it is tested for

Each study’s main condition, where its own words name it.

Parkinson Disease: 2
Schizophrenia: 1

Who runs them

Industry 6 · Other 4

Pfizer (6) · Yale University (1) · University of Zurich (1) · Milton S. Hershey Medical Center (1) · Invicro (1)

Studies

Open first, then newest update. How each study uses PF-06412562 is read from its arms, and is right about nine times in ten.

Testing it · 10

A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for SchizophreniaCompletedPhase 2Yale UniversityNCT04457310Written as CVL-562 (PF-06412562) 1 mg
Effects of PF-06412562 on Value-based Decision-making in Healthy IndividualsCompletedPhase 1University of ZurichNCT03181841Written as PF-06412562
PF 06412562 in Subjects With Advanced Stage Parkinson's DiseaseCompletedPhase 1Milton S. Hershey Medical CenterNCT03665454Written as PF-06412562
D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562CompletedEarly Phase 1InvicroNCT03686501Written as PF-06412562
A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With SchizophreniaCompletedPhase 1PfizerNCT02418819Written as PF-06412562 3mg BID
A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Healthy MalesTerminatedPhase 1PfizerNCT02306876Written as PF-06412562 3mg BID
A Healthy Volunteer Trial to Gain Information About the Blood Concentrations of PF-06412562 After Oral Administration of a Modified Release Formulation in Fasted and Fed ConditionsCompletedPhase 1PfizerNCT02201511Written as 10 mg PF-06412562 IR tablets
Efficacy, Safety And Tolerability Study In Subjects With Parkinson's DiseaseCompletedPhase 1PfizerNCT02006290Written as PF-06412562
A Study To Evaluate D1 Receptor Occupancy (RO) Following Single Dose of PF-06412562 In Healthy Male VolunteersCompletedPhase 1PfizerNCT02124213Written as 30 mg PF-06412562
A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult VolunteersCompletedPhase 1PfizerNCT01959594Written as 3 mg PF-06412562